ID   BUB1_HUMAN              Reviewed;        1085 AA.
AC   O43683; E9PC26; F5GXI5; O43430; O43643; O60626; Q53QE4;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   12-OCT-2022, entry version 205.
DE   RecName: Full=Mitotic checkpoint serine/threonine-protein kinase BUB1;
DE            Short=hBUB1;
DE            EC=2.7.11.1;
DE   AltName: Full=BUB1A;
GN   Name=BUB1; Synonyms=BUB1L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TYR-492.
RX   PubMed=9521327; DOI=10.1038/32688;
RA   Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V.,
RA   Markowitz S.D., Kinzler K.W., Vogelstein B.;
RT   "Mutations of mitotic checkpoint genes in human cancers.";
RL   Nature 392:300-303(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9790499;
RA   Ouyang B., Lan Z., Meadows J., Pan H., Fukasawa K., Li W., Dai W.;
RT   "Human Bub1: a putative spindle checkpoint kinase closely linked to cell
RT   proliferation.";
RL   Cell Growth Differ. 9:877-885(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9660858; DOI=10.1083/jcb.142.1.1;
RA   Taylor S.S., Ha E., McKeon F.;
RT   "The human homologue of Bub3 is required for kinetochore localization of
RT   Bub1 and a Mad3/Bub1-related protein kinase.";
RL   J. Cell Biol. 142:1-11(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION,
RP   INTERACTION WITH BUB3 AND MAD1L1, AND MUTAGENESIS OF LYS-821.
RC   TISSUE=Testis;
RX   PubMed=10198256; DOI=10.1006/bbrc.1999.0514;
RA   Seeley T.W., Wang L., Zhen J.Y.;
RT   "Phosphorylation of human MAD1 by the BUB1 kinase in vitro.";
RL   Biochem. Biophys. Res. Commun. 257:589-595(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANTS ASP-36 AND
RP   ARG-648.
RX   PubMed=10366450; DOI=10.1006/geno.1999.5831;
RA   Cahill D.P., da Costa L.T., Carson-Walter E.B., Kinzler K.W.,
RA   Vogelstein B., Lengauer C.;
RT   "Characterization of MAD2B and other mitotic spindle checkpoint genes.";
RL   Genomics 58:181-187(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 276-1085.
RX   PubMed=9441741; DOI=10.1006/geno.1997.5068;
RA   Pangilinan F., Li Q., Weaver T., Lewis B.C., Dang C.V., Spencer F.;
RT   "Mammalian BUB1 protein kinases: map positions and in vivo expression.";
RL   Genomics 46:379-388(1997).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15020684; DOI=10.1242/jcs.01006;
RA   Johnson V.L., Scott M.I., Holt S.V., Hussein D., Taylor S.S.;
RT   "Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and
RT   Mad2, and chromosome congression.";
RL   J. Cell Sci. 117:1577-1589(2004).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH BUB3.
RX   PubMed=15525512; DOI=10.1016/j.molcel.2004.09.031;
RA   Tang Z., Shu H., Oncel D., Chen S., Yu H.;
RT   "Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C
RT   inhibition by the spindle checkpoint.";
RL   Mol. Cell 16:387-397(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=15723797; DOI=10.1016/j.cub.2004.12.044;
RA   Kitajima T.S., Hauf S., Ohsugi M., Yamamoto T., Watanabe Y.;
RT   "Human Bub1 defines the persistent cohesion site along the mitotic
RT   chromosome by affecting Shugoshin localization.";
RL   Curr. Biol. 15:353-359(2005).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PLK1, PHOSPHORYLATION AT
RP   THR-609, AND MUTAGENESIS OF THR-609.
RX   PubMed=16760428; DOI=10.1091/mbc.e06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [14]
RP   SUBCELLULAR LOCATION, INTERACTION WITH KNL1, AND MUTAGENESIS OF ALA-106 AND
RP   LEU-122.
RX   PubMed=17981135; DOI=10.1016/j.devcel.2007.09.005;
RA   Kiyomitsu T., Obuse C., Yanagida M.;
RT   "Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic
RT   checkpoint through direct interaction with Bub1 and BubR1.";
RL   Dev. Cell 13:663-676(2007).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, DOMAIN KEN BOX, AND
RP   MUTAGENESIS OF LYS-535; GLU-536; ASN-537; LYS-625; GLU-626 AND ASN-627.
RX   PubMed=17158872; DOI=10.1074/jbc.m609376200;
RA   Qi W., Yu H.;
RT   "KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase by the
RT   anaphase-promoting complex/cyclosome.";
RL   J. Biol. Chem. 282:3672-3679(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-314, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-596 AND SER-655, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-593 AND SER-596, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION).
RX   PubMed=18922873; DOI=10.1128/jvi.01515-08;
RA   Hein J., Boichuk S., Wu J., Cheng Y., Freire R., Jat P.S., Roberts T.M.,
RA   Gjoerup O.V.;
RT   "Simian virus 40 large T antigen disrupts genome integrity and activates a
RT   DNA damage response via Bub1 binding.";
RL   J. Virol. 83:117-127(2009).
RN   [21]
RP   FUNCTION, MUTAGENESIS OF ALA-130, AND CHARACTERIZATION OF VARIANTS CYS-259
RP   AND ASN-265.
RX   PubMed=19487456; DOI=10.1083/jcb.200902128;
RA   Klebig C., Korinth D., Meraldi P.;
RT   "Bub1 regulates chromosome segregation in a kinetochore-independent
RT   manner.";
RL   J. Cell Biol. 185:841-858(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-314; SER-375; SER-563;
RP   SER-596 AND SER-655, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-563; SER-593 AND SER-596, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   FUNCTION.
RX   PubMed=20739936; DOI=10.1038/nature09390;
RA   Tsukahara T., Tanno Y., Watanabe Y.;
RT   "Phosphorylation of the CPC by Cdk1 promotes chromosome bi-orientation.";
RL   Nature 467:719-723(2010).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-593 AND SER-596, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-596, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307; SER-331; SER-525;
RP   SER-593; SER-596; SER-655; SER-661; SER-668 AND SER-672, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION).
RX   PubMed=26223641; DOI=10.1128/jvi.01524-15;
RA   Sun Z., Jha H.C., Robertson E.S.;
RT   "Bub1 in Complex with LANA Recruits PCNA To Regulate Kaposi's Sarcoma-
RT   Associated Herpesvirus Latent Replication and DNA Translesion Synthesis.";
RL   J. Virol. 89:10206-10218(2015).
RN   [30]
RP   VARIANTS PANCREATIC CANCER CYS-259 AND ASN-265.
RX   PubMed=12655561; DOI=10.1002/humu.9120;
RA   Hempen P.M., Kurpad H., Calhoun E.S., Abraham S., Kern S.E.;
RT   "A double missense variation of the BUB1 gene and a defective mitotic
RT   spindle checkpoint in the pancreatic cancer cell line Hs766T.";
RL   Hum. Mutat. 21:445-445(2003).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-20 AND ASP-534.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that performs 2 crucial
CC       functions during mitosis: it is essential for spindle-assembly
CC       checkpoint signaling and for correct chromosome alignment. Has a key
CC       role in the assembly of checkpoint proteins at the kinetochore, being
CC       required for the subsequent localization of CENPF, BUB1B, CENPE and
CC       MAD2L1. Required for the kinetochore localization of PLK1. Required for
CC       centromeric enrichment of AUKRB in prometaphase. Plays an important
CC       role in defining SGO1 localization and thereby affects sister chromatid
CC       cohesion. Acts as a substrate for anaphase-promoting complex or
CC       cyclosome (APC/C) in complex with its activator CDH1 (APC/C-Cdh1).
CC       Necessary for ensuring proper chromosome segregation and binding to
CC       BUB3 is essential for this function. Can regulate chromosome
CC       segregation in a kinetochore-independent manner. Can phosphorylate
CC       BUB3. The BUB1-BUB3 complex plays a role in the inhibition of APC/C
CC       when spindle-assembly checkpoint is activated and inhibits the
CC       ubiquitin ligase activity of APC/C by phosphorylating its activator
CC       CDC20. This complex can also phosphorylate MAD1L1. Kinase activity is
CC       essential for inhibition of APC/CCDC20 and for chromosome alignment but
CC       does not play a major role in the spindle-assembly checkpoint activity.
CC       Mediates cell death in response to chromosome missegregation and acts
CC       to suppress spontaneous tumorigenesis. {ECO:0000269|PubMed:10198256,
CC       ECO:0000269|PubMed:15020684, ECO:0000269|PubMed:15525512,
CC       ECO:0000269|PubMed:15723797, ECO:0000269|PubMed:16760428,
CC       ECO:0000269|PubMed:17158872, ECO:0000269|PubMed:19487456,
CC       ECO:0000269|PubMed:20739936}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Autophosphorylated when the cells enters mitosis.
CC   -!- SUBUNIT: Interacts with BUB3 and KNL1. Interacts (when phosphorylated)
CC       with PLK1. The BUB1-BUB3 complex interacts with MAD1L1.
CC       {ECO:0000305|PubMed:10198256, ECO:0000305|PubMed:15525512,
CC       ECO:0000305|PubMed:16760428, ECO:0000305|PubMed:17981135}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SV40 Large T antigen;
CC       this interaction induces activation of a DNA damage response and
CC       promotes p53/TP53 stabilization and phosphorylation.
CC       {ECO:0000269|PubMed:18922873}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein
CC       LANA1. {ECO:0000269|PubMed:26223641}.
CC   -!- INTERACTION:
CC       O43683; O95376: ARIH2; NbExp=5; IntAct=EBI-748936, EBI-711158;
CC       O43683; O60566: BUB1B; NbExp=3; IntAct=EBI-748936, EBI-1001438;
CC       O43683; O43684: BUB3; NbExp=5; IntAct=EBI-748936, EBI-1050987;
CC       O43683; P46108: CRK; NbExp=2; IntAct=EBI-748936, EBI-886;
CC       O43683; Q8NG31: KNL1; NbExp=2; IntAct=EBI-748936, EBI-1001161;
CC       O43683; Q8NG31-2: KNL1; NbExp=3; IntAct=EBI-748936, EBI-10973816;
CC       O43683; P03070; Xeno; NbExp=2; IntAct=EBI-748936, EBI-617698;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere, kinetochore.
CC       Note=Nuclear in interphase cells. Accumulates gradually during G1 and S
CC       phase of the cell cycle, peaks at G2/M, and drops dramatically after
CC       mitosis. Localizes to the outer kinetochore. Kinetochore localization
CC       is required for normal mitotic timing and checkpoint response to
CC       spindle damage and occurs very early in prophase. AURKB, KNL1 and
CC       INCENP are required for kinetochore localization (By similarity).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O43683-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43683-2; Sequence=VSP_054761;
CC       Name=3;
CC         IsoId=O43683-3; Sequence=VSP_054760;
CC   -!- TISSUE SPECIFICITY: High expression in testis and thymus, less in
CC       colon, spleen, lung and small intestine. Expressed in fetal thymus,
CC       bone marrow, heart, liver, spleen and thymus. Expression is associated
CC       with cells/tissues with a high mitotic index.
CC   -!- INDUCTION: Inhibited by phorbol 12-myristate 13-acetate (PMA).
CC   -!- DOMAIN: The KEN box is required for its ubiquitination and degradation.
CC       {ECO:0000269|PubMed:17158872}.
CC   -!- DOMAIN: BUB1 N-terminal domain directs kinetochore localization and
CC       binding to BUB3. {ECO:0000269|PubMed:17158872}.
CC   -!- PTM: Upon spindle-assembly checkpoint activation it is
CC       hyperphosphorylated and its kinase activity toward CDC20 is stimulated.
CC       Phosphorylation at Thr-609 is required for interaction with PLK1,
CC       phosphorylation at this site probably creates a binding site for the
CC       POLO-box domain of PLK1, thus enhancing the PLK1-BUB1 interaction.
CC       {ECO:0000269|PubMed:10198256, ECO:0000269|PubMed:15525512,
CC       ECO:0000269|PubMed:16760428}.
CC   -!- PTM: Ubiquitinated and degraded during mitotic exit by APC/C-Cdh1.
CC       {ECO:0000269|PubMed:17158872}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. BUB1 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BUB1ID853ch2q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF046078; AAC12729.1; -; mRNA.
DR   EMBL; AF043294; AAB97855.2; -; mRNA.
DR   EMBL; AF053305; AAC06259.1; -; mRNA.
DR   EMBL; AF047471; AAC03122.1; -; mRNA.
DR   EMBL; AF139363; AAD43675.1; -; Genomic_DNA.
DR   EMBL; AF139349; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139350; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139351; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139352; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139353; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139354; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139355; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139356; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139357; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139358; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139359; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139360; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139361; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139362; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AC114776; AAY14706.1; -; Genomic_DNA.
DR   EMBL; AC226101; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471237; EAW50355.1; -; Genomic_DNA.
DR   EMBL; BC028201; AAH28201.1; -; mRNA.
DR   EMBL; AF011387; AAC39546.1; -; mRNA.
DR   CCDS; CCDS33273.1; -. [O43683-1]
DR   CCDS; CCDS62984.1; -. [O43683-3]
DR   CCDS; CCDS62985.1; -. [O43683-2]
DR   RefSeq; NP_001265546.1; NM_001278617.1. [O43683-2]
DR   RefSeq; NP_004327.1; NM_004336.4. [O43683-1]
DR   PDB; 2LAH; NMR; -; A=1-150.
DR   PDB; 4A1G; X-ray; 2.60 A; A/B/C/D=1-150.
DR   PDB; 4QPM; X-ray; 2.20 A; A/B=740-1085.
DR   PDB; 4R8Q; X-ray; 2.31 A; A=724-1085.
DR   PDB; 5DMZ; X-ray; 2.40 A; A/B=726-1085.
DR   PDB; 6F7B; X-ray; 2.00 A; A=726-1085.
DR   PDB; 7B1F; X-ray; 1.75 A; C/D=455-479.
DR   PDB; 7B1H; X-ray; 2.40 A; C/D/G/H=455-479.
DR   PDB; 7B1J; X-ray; 2.90 A; C/D=455-479.
DR   PDBsum; 2LAH; -.
DR   PDBsum; 4A1G; -.
DR   PDBsum; 4QPM; -.
DR   PDBsum; 4R8Q; -.
DR   PDBsum; 5DMZ; -.
DR   PDBsum; 6F7B; -.
DR   PDBsum; 7B1F; -.
DR   PDBsum; 7B1H; -.
DR   PDBsum; 7B1J; -.
DR   AlphaFoldDB; O43683; -.
DR   BMRB; O43683; -.
DR   SMR; O43683; -.
DR   BioGRID; 107164; 120.
DR   CORUM; O43683; -.
DR   DIP; DIP-24206N; -.
DR   ELM; O43683; -.
DR   IntAct; O43683; 95.
DR   MINT; O43683; -.
DR   STRING; 9606.ENSP00000302530; -.
DR   BindingDB; O43683; -.
DR   ChEMBL; CHEMBL1772932; -.
DR   GuidetoPHARMACOLOGY; 1949; -.
DR   GlyGen; O43683; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O43683; -.
DR   PhosphoSitePlus; O43683; -.
DR   BioMuta; BUB1; -.
DR   EPD; O43683; -.
DR   jPOST; O43683; -.
DR   MassIVE; O43683; -.
DR   MaxQB; O43683; -.
DR   PaxDb; O43683; -.
DR   PeptideAtlas; O43683; -.
DR   PRIDE; O43683; -.
DR   ProteomicsDB; 19348; -.
DR   ProteomicsDB; 24432; -.
DR   ProteomicsDB; 49112; -. [O43683-1]
DR   Antibodypedia; 1133; 554 antibodies from 40 providers.
DR   DNASU; 699; -.
DR   Ensembl; ENST00000302759.11; ENSP00000302530.6; ENSG00000169679.15. [O43683-1]
DR   Ensembl; ENST00000409311.5; ENSP00000386701.1; ENSG00000169679.15. [O43683-2]
DR   Ensembl; ENST00000535254.6; ENSP00000441013.1; ENSG00000169679.15. [O43683-3]
DR   GeneID; 699; -.
DR   KEGG; hsa:699; -.
DR   MANE-Select; ENST00000302759.11; ENSP00000302530.6; NM_004336.5; NP_004327.1.
DR   UCSC; uc002tgc.5; human. [O43683-1]
DR   CTD; 699; -.
DR   DisGeNET; 699; -.
DR   GeneCards; BUB1; -.
DR   HGNC; HGNC:1148; BUB1.
DR   HPA; ENSG00000169679; Group enriched (bone marrow, lymphoid tissue, testis).
DR   MalaCards; BUB1; -.
DR   MIM; 602452; gene.
DR   neXtProt; NX_O43683; -.
DR   OpenTargets; ENSG00000169679; -.
DR   Orphanet; 1052; Mosaic variegated aneuploidy syndrome.
DR   PharmGKB; PA81; -.
DR   VEuPathDB; HostDB:ENSG00000169679; -.
DR   eggNOG; KOG1166; Eukaryota.
DR   GeneTree; ENSGT00940000157865; -.
DR   HOGENOM; CLU_296458_0_0_1; -.
DR   InParanoid; O43683; -.
DR   OMA; RSWSYET; -.
DR   OrthoDB; 1411806at2759; -.
DR   PhylomeDB; O43683; -.
DR   TreeFam; TF105455; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; O43683; -.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; O43683; -.
DR   SIGNOR; O43683; -.
DR   BioGRID-ORCS; 699; 560 hits in 1129 CRISPR screens.
DR   ChiTaRS; BUB1; human.
DR   EvolutionaryTrace; O43683; -.
DR   GeneWiki; BUB1; -.
DR   GenomeRNAi; 699; -.
DR   Pharos; O43683; Tchem.
DR   PRO; PR:O43683; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O43683; protein.
DR   Bgee; ENSG00000169679; Expressed in ventricular zone and 111 other tissues.
DR   ExpressionAtlas; O43683; baseline and differential.
DR   Genevisible; O43683; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0051754; P:meiotic sister chromatid cohesion, centromeric; IBA:GO_Central.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0051983; P:regulation of chromosome segregation; IMP:UniProtKB.
DR   GO; GO:0007063; P:regulation of sister chromatid cohesion; IDA:UniProtKB.
DR   IDEAL; IID00406; -.
DR   InterPro; IPR015661; Bub1/Mad3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR013212; Mad3/Bub1_I.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR14030; PTHR14030; 1.
DR   Pfam; PF08311; Mad3_BUB1_I; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00777; Mad3_BUB1_I; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51489; BUB1_N; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell cycle;
KW   Cell division; Centromere; Chromosome; Chromosome partition;
KW   Host-virus interaction; Kinase; Kinetochore; Mitosis; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..1085
FT                   /note="Mitotic checkpoint serine/threonine-protein kinase
FT                   BUB1"
FT                   /id="PRO_0000085671"
FT   DOMAIN          11..182
FT                   /note="BUB1 N-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00822"
FT   DOMAIN          787..1085
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..146
FT                   /note="Necessary for kinetochore localization"
FT   REGION          99..132
FT                   /note="Necessary for interaction with KNL1"
FT                   /evidence="ECO:0000269|PubMed:17981135"
FT   REGION          229..256
FT                   /note="Necessary for interaction with BUB3"
FT   REGION          305..333
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          458..476
FT                   /note="Essential for loading of BUBR1, MAD1L1 and MAD2L1 to
FT                   kinetochores"
FT   REGION          538..570
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           58..65
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           535..537
FT                   /note="KEN box 1"
FT   MOTIF           625..627
FT                   /note="KEN box 2"
FT   ACT_SITE        917
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         793..801
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         821
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         314
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         563
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         593
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         596
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         609
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:16760428"
FT   MOD_RES         655
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         661
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         668
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         672
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         10..29
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054760"
FT   VAR_SEQ         876..932
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054761"
FT   VARIANT         20
FT                   /note="G -> D (in dbSNP:rs35890336)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040400"
FT   VARIANT         36
FT                   /note="E -> D (in colorectal cancer; dbSNP:rs1801328)"
FT                   /evidence="ECO:0000269|PubMed:10366450"
FT                   /id="VAR_008849"
FT   VARIANT         259
FT                   /note="Y -> C (in pancreatic cancer; associated with N-265;
FT                   failure to rescue the spindle-assembly checkpoint activity
FT                   as a result of a deficient recruitment of MAD2L1 and BUBR1
FT                   to kinetochores; efficient restoration of chromosome
FT                   congression; reduced binding to BUB3; rescue of the ability
FT                   of kinetochores to bind SGO1 and CENPF but not MCAK)"
FT                   /evidence="ECO:0000269|PubMed:12655561,
FT                   ECO:0000269|PubMed:19487456"
FT                   /id="VAR_015687"
FT   VARIANT         265
FT                   /note="H -> N (in pancreatic cancer; associated with C-259;
FT                   complete rescue of the spindle-assembly checkpoint
FT                   activity; increased rate of chromosome congression errors)"
FT                   /evidence="ECO:0000269|PubMed:12655561,
FT                   ECO:0000269|PubMed:19487456"
FT                   /id="VAR_015688"
FT   VARIANT         492
FT                   /note="S -> Y (in colorectal cancer; dbSNP:rs121909055)"
FT                   /evidence="ECO:0000269|PubMed:9521327"
FT                   /id="VAR_008850"
FT   VARIANT         534
FT                   /note="N -> D (in dbSNP:rs36109304)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040401"
FT   VARIANT         648
FT                   /note="P -> R (in colorectal cancer; dbSNP:rs376649190)"
FT                   /evidence="ECO:0000269|PubMed:10366450"
FT                   /id="VAR_008851"
FT   MUTAGEN         106
FT                   /note="A->D,W: Loss of interaction with KNL1."
FT                   /evidence="ECO:0000269|PubMed:17981135"
FT   MUTAGEN         122
FT                   /note="L->G: Loss of interaction with KNL1."
FT                   /evidence="ECO:0000269|PubMed:17981135"
FT   MUTAGEN         130
FT                   /note="A->S: Partial rescue of the spindle-assembly
FT                   checkpoint activity. Increased rate of chromosome
FT                   congression errors. Impaired localization to kinetochores
FT                   and loss of kinetochore binding of CENPF, SGO1 and BUBR1
FT                   but not of MCAK, MAD1L1 or MAD2L1."
FT                   /evidence="ECO:0000269|PubMed:19487456"
FT   MUTAGEN         535
FT                   /note="K->A: Loss of ubiquitination and CDH1-dependent
FT                   degradation; when associated with A-536 and A-537."
FT                   /evidence="ECO:0000269|PubMed:17158872"
FT   MUTAGEN         536
FT                   /note="E->A: Loss of ubiquitination and CDH1-dependent
FT                   degradation; when associated with A-535 and A-537."
FT                   /evidence="ECO:0000269|PubMed:17158872"
FT   MUTAGEN         537
FT                   /note="N->A: Loss of ubiquitination and CDH1-dependent
FT                   degradation; when associated with A-535 and A-536."
FT                   /evidence="ECO:0000269|PubMed:17158872"
FT   MUTAGEN         609
FT                   /note="T->A: Diminished interaction with PLK1."
FT                   /evidence="ECO:0000269|PubMed:16760428"
FT   MUTAGEN         625
FT                   /note="K->A: Loss of ubiquitination and CDH1-dependent
FT                   degradation; when associated with A-626 and A-627."
FT                   /evidence="ECO:0000269|PubMed:17158872"
FT   MUTAGEN         626
FT                   /note="E->A: Loss of ubiquitination and CDH1-dependent
FT                   degradation; when associated with A-625 and A-627."
FT                   /evidence="ECO:0000269|PubMed:17158872"
FT   MUTAGEN         627
FT                   /note="N->A: Loss of ubiquitination and CDH1-dependent
FT                   degradation; when associated with A-625 and A-626."
FT                   /evidence="ECO:0000269|PubMed:17158872"
FT   MUTAGEN         821
FT                   /note="K->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:10198256"
FT   CONFLICT        70
FT                   /note="S -> T (in Ref. 5; AAC06259)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        276..279
FT                   /note="MKRK -> IRHE (in Ref. 9; AAC39546)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..14
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           23..35
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           43..56
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           60..62
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           66..76
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           82..90
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   TURN            91..97
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           99..111
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           115..127
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           133..145
FT                   /evidence="ECO:0007829|PDB:4A1G"
FT   HELIX           462..471
FT                   /evidence="ECO:0007829|PDB:7B1F"
FT   HELIX           472..475
FT                   /evidence="ECO:0007829|PDB:7B1F"
FT   STRAND          736..739
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           744..752
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           758..760
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          764..766
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          779..782
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          785..796
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          799..805
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          817..825
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           828..840
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           843..848
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          852..857
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          862..866
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           874..881
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          884..886
FT                   /evidence="ECO:0007829|PDB:5DMZ"
FT   HELIX           891..910
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           920..922
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          923..925
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           927..931
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          940..944
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           953..955
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          960..962
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          967..971
FT                   /evidence="ECO:0007829|PDB:4QPM"
FT   HELIX           974..977
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           985..1000
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          1006..1008
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   STRAND          1013..1016
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           1025..1036
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           1047..1061
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   TURN            1062..1065
FT                   /evidence="ECO:0007829|PDB:6F7B"
FT   HELIX           1066..1081
FT                   /evidence="ECO:0007829|PDB:6F7B"
SQ   SEQUENCE   1085 AA;  122375 MW;  38AE5E1F88C53BDC CRC64;
     MDTPENVLQM LEAHMQSYKG NDPLGEWERY IQWVEENFPE NKEYLITLLE HLMKEFLDKK
     KYHNDPRFIS YCLKFAEYNS DLHQFFEFLY NHGIGTLSSP LYIAWAGHLE AQGELQHASA
     VLQRGIQNQA EPREFLQQQY RLFQTRLTET HLPAQARTSE PLHNVQVLNQ MITSKSNPGN
     NMACISKNQG SELSGVISSA CDKESNMERR VITISKSEYS VHSSLASKVD VEQVVMYCKE
     KLIRGESEFS FEELRAQKYN QRRKHEQWVN EDRHYMKRKE ANAFEEQLLK QKMDELHKKL
     HQVVETSHED LPASQERSEV NPARMGPSVG SQQELRAPCL PVTYQQTPVN MEKNPREAPP
     VVPPLANAIS AALVSPATSQ SIAPPVPLKA QTVTDSMFAV ASKDAGCVNK STHEFKPQSG
     AEIKEGCETH KVANTSSFHT TPNTSLGMVQ ATPSKVQPSP TVHTKEALGF IMNMFQAPTL
     PDISDDKDEW QSLDQNEDAF EAQFQKNVRS SGAWGVNKII SSLSSAFHVF EDGNKENYGL
     PQPKNKPTGA RTFGERSVSR LPSKPKEEVP HAEEFLDDST VWGIRCNKTL APSPKSPGDF
     TSAAQLASTP FHKLPVESVH ILEDKENVVA KQCTQATLDS CEENMVVPSR DGKFSPIQEK
     SPKQALSSHM YSASLLRLSQ PAAGGVLTCE AELGVEACRL TDTDAAIAED PPDAIAGLQA
     EWMQMSSLGT VDAPNFIVGN PWDDKLIFKL LSGLSKPVSS YPNTFEWQCK LPAIKPKTEF
     QLGSKLVYVH HLLGEGAFAQ VYEATQGDLN DAKNKQKFVL KVQKPANPWE FYIGTQLMER
     LKPSMQHMFM KFYSAHLFQN GSVLVGELYS YGTLLNAINL YKNTPEKVMP QGLVISFAMR
     MLYMIEQVHD CEIIHGDIKP DNFILGNGFL EQDDEDDLSA GLALIDLGQS IDMKLFPKGT
     IFTAKCETSG FQCVEMLSNK PWNYQIDYFG VAATVYCMLF GTYMKVKNEG GECKPEGLFR
     RLPHLDMWNE FFHVMLNIPD CHHLPSLDLL RQKLKKVFQQ HYTNKIRALR NRLIVLLLEC
     KRSRK
//
